Predict your next investment

Corporation
COMPUTER HARDWARE & SERVICES | IT Services / IT Solutions & Software Development
agilent.com

See what CB Insights has to offer

Investments

25

Portfolio Exits

7

Partners & Customers

10

About Agilent Technologies

Agilent Technologies (NYSE: A) provides instruments, software, services, and consumables for the entire laboratory workflow, serving the life sciences, diagnostics, and applied chemical markets.

Agilent Technologies Headquarter Location

5301 Stevens Creek Boulevard

Santa Clara, California, 95051,

United States

408-345-8886

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Agilent Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Agilent Technologies in 5 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Industrial SynBio

382 items

Synthetic biology focused on replacing industrial and commercial materials.

M

Medical Devices

3,872 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

H

Health & Wellness Assessment

77 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx

Latest Agilent Technologies News

DNA and RNA sample preparation market to reach US$ 932.0 Mn by 2028 at a CAGR of 5.5% Overall Study 2021-2028 |  Agilent Technologies, Becton, Bio-Rad Laboratories, F. Hoffmann-La Roche

Sep 24, 2021

|  Agilent Technologies, Becton, Bio-Rad Laboratories, F. Hoffmann-La Roche DNA and RNA samples are necessary for variety of applications in drug research and development and cancer studies. High quality DNA and RNA samples are important for a wide variety of research and clinical applications. Biological studies require purified and isolated nucleic acids as the first step and in all recombinant DNA techniques. The extraction of nucleic acids from biological material requires cell lysis, inactivation of cellular nucleases, and separation of the desired nucleic acid from cellular debris. Methods for purifying nucleic acids from cell extracts are often combinations of extraction/precipitation, chromatography, centrifugation, electrophoresis, and affinity separation. Pure nucleic acid has applications in emerging fields such as genetic engineering, molecular diagnosis, forensics, and research related to life sciences. Request Sample Copy of DNA and RNA Sample Preparation Report @ Increasing funding in life science research is expected to boost growth of the global DNA and RNA sample preparation market over the forecast period. For instance, in February 2020, Purdue-affiliated Amplified Sciences LLC and Brightlamp Inc. received approvals for up to US$ 250,000 each from the Purdue Foundry Investment Fund for R&D in life science technologies. Moreover, collaborative efforts and initiatives to identify therapies for difficult-to-treat illnesses is also expected to aid in growth of the market. For instance, in February 2020, Cellectricon (Molndal), a Sweden–based pharmaceutical company collaborated with StressMarq Biosciences, a Canada-based life sciences reagents supplier, for R&D in neurodegenerative diseases. High cost of products and low investments are expected to hinder growth of the global DNA and RNA sample preparation market. Researches in the life science sector are complex and have uncertainties in terms results. This in turn increases R&D and product cost and deters users from investing in such expensive products. Moreover, challenges in handling RNA are also expected to limit growth of the market. The presence of RNases is a major challenge in isolating, manipulating, or analyzing RNA. RNases are extremely stable and very active nucleases capable of degrading the RNA. Request PDF Report Brochure @ Using quality control tools to obtain information on nucleic acid quantification, integrity, and sizing of fragments in next-generation sequencing is expected to offer lucrative growth opportunities for players in the market. Quality control tools can aid in maintaining clean samples that are free from contaminants. Moreover, market players can also focus on digitalization in the life science sector through adoption of technologies such as wearable devices and artificial intelligence. Digital technology can be used for routine tasks such regulatory filings. Major players operating in the global DNA and RNA sample preparation market include, Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., DiaSorin S.p.A, F. Hoffmann-La Roche, Miroculus, Inc., Illumina, Inc., PerkinElmer, Inc., QIAGEN, Sigma Aldrich Corp., Tecan Group AG, and Thermo Fisher Scientific, Inc. Major players in the market are focused on launching new products to expand their product portfolio. For instance, in February 2020, Miroculus, Inc. launched Miro Canvas, a system that can simplify, automate, and miniaturize complex protocols such as next generation sequencing library preparation, at the Advances in Genome Biology and Technology conference held in the U.S. Major players in the market are also focused on adopting collaboration strategies to expand their product portfolio. For instance, in March 2020, Fluidigm Corporation, a provider of microfluidics technology, partnered with Next Gen Diagnostics, a provider of automation in pathogen bioinformatics, under which the later will use the Fluidigm Juno system for pathogen whole genome sequencing sample preparation in exchange of milestone payments starting in 2020 and additional revenue to Fluidigm Corp. Buy This Complete A Business Report With Flat US $2000 Off @ Reasons to Purchase this Report • Current and future of global DNA and RNA Sample Preparation market outlook in the developed and emerging markets • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period. • Regions/countries that are expected to witness the fastest growth rates during the forecast period • The latest developments, market shares, and strategies that are employed by the major market players Table Of Content Key Questions Answered in This Report on DNA and RNA Sample Preparation Market • How much revenue will the global DNA and RNA Sample Preparation Market generate by the end of the forecast period? • What regions currently contribute the maximum share to the overall DNA and RNA Sample Preparation Market? • What are the indicators expected to drive the global DNA and RNA Sample Preparation Market? • Which region is likely to be a lucrative market during the forecast period? • What are the essential strategies incorporated by key stakeholders in the global DNA and RNA Sample Preparation Market to expand their geographical presence? • What are the major advancements witnessed in the global DNA and RNA Sample Preparation Market? • This report answers these questions and more about the global DNA and RNA Sample Preparation Market, aiding major stakeholders and key players in making the right decisions and strategizing for the advancement of their business. Customization of the Report In case of any  Queries or Customization Requirements  please connect with our sales team, who will ensure that your requirements are met. Also, Research Report Examines: • By Product Type, Applications & Growth Factors • Industry Status and Outlook for Major Applications / End Users / Usage Area Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. Editor Details

Agilent Technologies Investments

25 Investments

Agilent Technologies has made 25 investments. Their latest investment was in RareCyte as part of their Private Equity - IV on September 9, 2021.

CBI Logo

Agilent Technologies Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/9/2021

Private Equity - IV

RareCyte

$24M

Yes

3

7/13/2021

Series C

MOBILion Systems

$60M

No

3

4/16/2021

Series A - II

Molecular Assemblies

$24M

No

3

9/17/2020

Series A - III

Subscribe to see more

$99M

Subscribe to see more

10

8/20/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/9/2021

7/13/2021

4/16/2021

9/17/2020

8/20/2020

Round

Private Equity - IV

Series C

Series A - II

Series A - III

Series A

Company

RareCyte

MOBILion Systems

Molecular Assemblies

Subscribe to see more

Subscribe to see more

Amount

$24M

$60M

$24M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

3

3

10

10

Agilent Technologies Portfolio Exits

7 Portfolio Exits

Agilent Technologies has 7 portfolio exits. Their latest portfolio exit was Akoya Biosciences on April 16, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/16/2021

IPO

$991

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

4/16/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

IPO

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Agilent Technologies Acquisitions

34 Acquisitions

Agilent Technologies acquired 34 companies. Their latest acquisition was Resolution Bioscience on March 02, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/2/2021

$991

Acquired

13

7/11/2019

$991

Acquired

6

9/26/2018

Acquired

$991

$57.89M

Acquired

7

6/28/2018

Subscribe to see more

$99M

Subscribe to see more

10

5/30/2018

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/2/2021

7/11/2019

9/26/2018

6/28/2018

5/30/2018

Investment Stage

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$57.89M

$99M

$99M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

13

6

7

10

10

Agilent Technologies Partners & Customers

10 Partners and customers

Agilent Technologies has 10 strategic partners and customers. Agilent Technologies recently partnered with Thomas Scientific on July 7, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

7/20/2021

Supplier

Thomas Scientific

United States

08:44 ET Thomas Scientific Lands Agilent as Distribution Partner

`` We are excited for this new strategic partnership with Thomas Scientific , '' stated Michael Pietroforte , Genomics Indirect Channel Manager at Agilent Technologies .

2

3/31/2021

Licensor

Oxford BioDynamics

United Kingdom

Oxford BioDynamics signs supply and resale agreement with Agilent Technologies, and launches EpiSwitch® Explorer Array Kit for R&D use

Kevin Meldrum , VP/GM of Agilent said : `` Agilent Technologies is the premier provider of custom microarrays and we are excited to secure this partnership with Oxford BioDynamics Plc demonstrating how arrays can enable the development of new technologies , such as EpiSwitch ® Explorer Array , beyond gene expression and CGH . ''

3

1/28/2021

Partner

Mammoth Biosciences

United States

Mammoth Biosciences and Agilent Partner on High-Throughput CRISPR-Based SARS-CoV-2 Diagnostic Test

Mammoth Biosciences , Inc. today announced a co-marketing agreement with Agilent Technologies to support the anticipated launch of a complete CRISPR-based SARS-CoV-2 diagnostic solution comprising Agilent Technologies 's Bravo automation workstation and Mammoth Biosciences , Inc. ' DETECTR BOOSTTM assay .

4

1/28/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

10/20/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/20/2021

3/31/2021

1/28/2021

1/28/2021

10/20/2020

Type

Supplier

Licensor

Partner

Partner

Partner

Business Partner

Thomas Scientific

Oxford BioDynamics

Mammoth Biosciences

Country

United States

United Kingdom

United States

Subscribe to see more

Subscribe to see more

News Snippet

08:44 ET Thomas Scientific Lands Agilent as Distribution Partner

`` We are excited for this new strategic partnership with Thomas Scientific , '' stated Michael Pietroforte , Genomics Indirect Channel Manager at Agilent Technologies .

Oxford BioDynamics signs supply and resale agreement with Agilent Technologies, and launches EpiSwitch® Explorer Array Kit for R&D use

Kevin Meldrum , VP/GM of Agilent said : `` Agilent Technologies is the premier provider of custom microarrays and we are excited to secure this partnership with Oxford BioDynamics Plc demonstrating how arrays can enable the development of new technologies , such as EpiSwitch ® Explorer Array , beyond gene expression and CGH . ''

Mammoth Biosciences and Agilent Partner on High-Throughput CRISPR-Based SARS-CoV-2 Diagnostic Test

Mammoth Biosciences , Inc. today announced a co-marketing agreement with Agilent Technologies to support the anticipated launch of a complete CRISPR-based SARS-CoV-2 diagnostic solution comprising Agilent Technologies 's Bravo automation workstation and Mammoth Biosciences , Inc. ' DETECTR BOOSTTM assay .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

3

4

10

10

Agilent Technologies Team

14 Team Members

Agilent Technologies has 14 team members, including current Senior Director, Nalini M..

Name

Work History

Title

Status

Nalini M.

Senior Director

Current

Lars Holmqvist

Bain Capital, and Dako Denmark

President, Senior Vice President

Former

Nick Roelofs

President

Former

Young Sohn

President

Former

James Mahon

Chief Technology Officer

Former

Name

Nalini M.

Lars Holmqvist

Nick Roelofs

Young Sohn

James Mahon

Work History

Bain Capital, and Dako Denmark

Title

Senior Director

President, Senior Vice President

President

President

Chief Technology Officer

Status

Current

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.